POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-134804 |   Pharmaceuticals and Medical

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Point-of-Care Infectious Disease Diagnostics or Testing Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET

7.1 GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Abbott

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Thermo Fisher Scientific Inc

16.3 Sight Diagnostics Ltd

16.4 Trivitron Healthcare

16.5 bioMérieux SA

16.6 Chembio Diagnostics Inc

16.7 Gene POC

16.8 Siemens Healthineers

16.9 Trinity Biotech

16.10 OJ-Bio Ltd

16.11 F Hoffmann-La Roche Ltd

16.12 BD & Company

16.13 Quest Diagnostics Inc

16.14 Bio-Rad Labs Inc

16.15 Cardinal Health

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

Major Types Covered
HBV POC
HIV POC
Clostridium difficile POC
HPV POC
Respiratory syncytial virus (RSV) POC
Other Infectious Disease POC
Influenza/Flu POC
Pneumonia or Streptococcus associated infections

Major Downstream Industry Covered
Clinics
Assisted Living Healthcare Facilities
Home
Laboratories
Hospitals
Others

Companies

Abbott
Thermo Fisher Scientific Inc
Sight Diagnostics Ltd
Trivitron Healthcare
bioMérieux SA
Chembio Diagnostics Inc
Gene POC
Siemens Healthineers
Trinity Biotech
OJ-Bio Ltd
F Hoffmann-La Roche Ltd
BD & Company
Quest Diagnostics Inc
Bio-Rad Labs Inc
Cardinal Health

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE
  • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY
  • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH
  • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING
  • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.